Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration

Recruiting

Phase 1

AH-001Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration

Sponsor:

AnHorn Medicines Co. Ltd.

Code:

NCT06927960

Conditions

Androgenetic Alopecia

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

AH-001 or placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-10. This information was provided to ClinicalTrials.gov by AnHorn Medicines Co. Ltd. on 2025-04-15.